Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.9 USD | -1.49% | -2.10% | -52.44% |
05-10 | UBS Cuts Price Target on ACADIA Pharmaceuticals to $25 From $27, Keeps Buy Rating | MT |
05-10 | Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-52.44% | 2.5B | |
+33.37% | 49.46B | |
+1.75% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.58% | 26.61B | |
-21.80% | 18.64B | |
+7.87% | 13.16B | |
+29.73% | 12.55B | |
+23.58% | 12.1B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- Transcript : ACADIA Pharmaceuticals Inc., Q3 2022 Earnings Call, Nov 02, 2022